Huang M, Huang Z, Miao S, Chen X, Tan Y, Zhou Y
Sci Rep. 2025; 15(1):4972.
PMID: 39929884
PMC: 11811422.
DOI: 10.1038/s41598-025-87669-2.
Zuo X, Li H, Xie S, Shi M, Guan Y, Liu H
Discov Oncol. 2025; 16(1):105.
PMID: 39890709
PMC: 11785873.
DOI: 10.1007/s12672-025-01856-1.
Ma H, Hong Y, Xu Z, Weng Z, Yang Y, Jin D
Sci Rep. 2025; 15(1):55.
PMID: 39747943
PMC: 11696456.
DOI: 10.1038/s41598-024-84050-7.
Gu X, Wang J, Guan J, Li G, Ma X, Ren Y
Cancer Med. 2024; 13(22):e70284.
PMID: 39540710
PMC: 11561968.
DOI: 10.1002/cam4.70284.
Li Y, Wang F, Geng Z, He T, Song Y, Wu J
Cell Biosci. 2024; 14(1):116.
PMID: 39256879
PMC: 11389268.
DOI: 10.1186/s13578-024-01298-2.
Prognosis comparison between hepatocellular carcinoma patients with microvascular invasion who received hepatectomy alone and those who underwent early PA-TACE: a retrospective cohort study.
Ma Z, Zhou W, Huang H, Yao Y
J Gastrointest Oncol. 2024; 15(3):1112-1121.
PMID: 38989441
PMC: 11231867.
DOI: 10.21037/jgo-24-282.
T cell-related ubiquitination genes as prognostic indicators in hepatocellular carcinoma.
Chen C, Chen Z, Zhou Z, Ye H, Xiong S, Hu W
Front Immunol. 2024; 15:1424752.
PMID: 38919610
PMC: 11196398.
DOI: 10.3389/fimmu.2024.1424752.
Identifying disulfidptosis subtypes in hepatocellular carcinoma through machine learning and preliminary exploration of its connection with immunotherapy.
Chen G, Zhang G, Zhu Y, Wu A, Fang J, Yin Z
Cancer Cell Int. 2024; 24(1):194.
PMID: 38831301
PMC: 11149214.
DOI: 10.1186/s12935-024-03387-1.
Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma.
Yang W, Wu Z, Cai S, Li Z, Wang W, Wu J
Front Immunol. 2024; 15:1354339.
PMID: 38638428
PMC: 11024352.
DOI: 10.3389/fimmu.2024.1354339.
Establishment and verification of a prognostic model based on coagulation and fibrinolysis-related genes in hepatocellular carcinoma.
Fan M, Lu L, Shang H, Lu Y, Yang Y, Wang X
Aging (Albany NY). 2024; 16(9):7578-7595.
PMID: 38568089
PMC: 11131995.
DOI: 10.18632/aging.205699.
A novel prognostic signature of coagulation-related genes leveraged by machine learning algorithms for lung squamous cell carcinoma.
Li G, He R, Huang Z, Huang H, Yang Z, Liu J
Heliyon. 2024; 10(6):e27595.
PMID: 38496840
PMC: 10944263.
DOI: 10.1016/j.heliyon.2024.e27595.
The sorafenib resistance-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma.
Luo T, Chen X, Pan W, Zhang S, Huang J
Cell Cycle. 2024; 23(2):150-168.
PMID: 38444181
PMC: 11037289.
DOI: 10.1080/15384101.2024.2309020.
Novel molecular hepatocellular carcinoma subtypes and RiskScore utilizing apoptosis-related genes.
Zhang M, Zhang S, Guo W, He Y
Sci Rep. 2024; 14(1):3913.
PMID: 38365931
PMC: 10873508.
DOI: 10.1038/s41598-024-54673-x.
A robust primary liver cancer subtype related to prognosis and drug response based on a multiple combined classifying strategy.
Deng J, Lai G, Zhang C, Li K, Zhu W, Xie B
Heliyon. 2024; 10(3):e25570.
PMID: 38352751
PMC: 10861988.
DOI: 10.1016/j.heliyon.2024.e25570.
Transcription Factor MAZ Potentiates the Upregulated NEIL3-mediated Aerobic Glycolysis, thereby Promoting Angiogenesis in Hepatocellular Carcinoma.
Zhang F, Wang B, Zhang W, Xu Y, Zhang C, Xue X
Curr Cancer Drug Targets. 2024; 24(12):1235-1249.
PMID: 38347781
DOI: 10.2174/0115680096265896231226062212.
Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.
Wei J, Wang J, Chen X, Zhang L, Peng M
PeerJ. 2024; 12:e16819.
PMID: 38317842
PMC: 10840499.
DOI: 10.7717/peerj.16819.
Development and validation of glycosyltransferase related-gene for the diagnosis and prognosis of head and neck squamous cell carcinoma.
He M, Wang L, Yue Z, Feng C, Dai G, Jiang J
Aging (Albany NY). 2024; 16(2):1750-1766.
PMID: 38244579
PMC: 10866440.
DOI: 10.18632/aging.205455.
Identifying the programmed cell death index of hepatocellular carcinoma for prognosis and therapy response improvement by machine learning: a bioinformatics analysis and experimental validation.
Shi Y, Feng Y, Qiu P, Zhao K, Li X, Deng Z
Front Immunol. 2024; 14:1298290.
PMID: 38170006
PMC: 10759150.
DOI: 10.3389/fimmu.2023.1298290.
Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.
Zhao J, Luo Z, Fu R, Zhou J, Chen S, Wang J
Eur J Med Res. 2023; 28(1):571.
PMID: 38057871
PMC: 10698993.
DOI: 10.1186/s40001-023-01535-3.
A new prognostic model for glioblastoma multiforme based on coagulation-related genes.
Zhou M, Deng Y, Fu Y, Liang R, Liu Y, Liao Q
Transl Cancer Res. 2023; 12(10):2898-2910.
PMID: 37969372
PMC: 10643966.
DOI: 10.21037/tcr-23-322.